Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Manganese-Doped Silica-Based Nanoparticles Promote the Efficacy of Antigen-Specific Immunotherapy.

Journal of immunology (Baltimore, Md. : 1950) - 1 Mar 2021

Chandra Janin, Teoh Siok Min, Kuo Paula, Tolley Lynn, Bashaw Abate Assefa, Tuong Zewen Kelvin, Liu Yang, Chen Zibin, Wells James W, Yu Chengzhong, Frazer Ian H, Yu Meihua

Abstract excerpt

Prophylactic human papillomavirus (HPV) vaccines are commercially available for prevention of infection with cancerogenic HPV genotypes but are not able to combat pre-existing HPV-associated disease. In this study, we designed a nanomaterial-based therapeutic HPV vaccine, comprising manganese (Mn4+)-doped silica nanoparticles (Mn4+-SNPs) and the viral neoantigen peptide GF001 derived from the HPV16 E7...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunization

Share to Manganese

Share to Nanoparticles

Share to Papillomavirus E7 Proteins

Share to Papillomavirus Vaccines

Share to Silicon Dioxide

Source

Identifiers

PMID: 33504616
DOI: 10.4049/jimmunol.2000355

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Manganese-Doped Silica-Based Nanoparticles Promote the Efficacy of Antigen-Specific Immunotherapy.PMID 33504616Read ↗

Neoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapySemantic proximity Read ↗

Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinomaSemantic proximity Read ↗

Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancersSemantic proximity Read ↗

Nanomedicine for Cancer and Autoimmune ImmunotherapySemantic proximity Read ↗

Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-VaccineSemantic proximity Read ↗

Efficient Nanovaccine Delivery in Cancer ImmunotherapySemantic proximity Read ↗

Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell-mediated Tumor ImmunotherapySemantic proximity Read ↗

Carrier-Free Nanovaccine: An Innovative Strategy for Ultrahigh Melanoma Neoantigen LoadingSemantic proximity Read ↗

Engineered Extracellular Vesicles Expressing Siglec-10 Camouflaged AIE Photosensitizer to Reprogram Macrophages to Active M1 Phenotype and Present Tumor-Associated Antigens for Photodynamic Immunotherapy.Semantic proximity Read ↗

Advancements in Nanoceria for Immunotherapy ApplicationsSemantic proximity Read ↗

Hybrid Bacterial Membrane Nanovaccine Reprograms the Tuberculosis Immune Microenvironment via CD40 to Surpass BCG ProtectionSemantic proximity Read ↗

Nanocatalytic Innate Immunity Activation by Mitochondrial DNA Oxidative Damage for Tumor‐Specific TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.